参考文献/References:
［1］ 中国医师协会肝癌专业委员会. 肝细胞癌合并肝静脉或下腔静脉癌栓多学科诊治中国专家共识（2019版）［J］. 中华消化外科杂志，2020，19：21-27．
［2］ Takeda K, Tsurumaru Y, Yamamoto Y, et al. Treatment of hepatocellular carcinoma with hepatic vein tumor thrombosis protruding into the inferior vena cava by conversion surgery following chemotherapy with regorafenib: a case report［J］. Clin J Gastroenterol, 2020, 13: 428-433.
［3］ 李 臻，石冰涛，张恒辉，等. 肝细胞癌患者血浆游离DNA高通量测序的分子分型研究［J］. 中华肝脏病杂志，2017，25：626-629．
［4］ Li Z, Xiao D, Li X, et al. Early recurrence detected in hepatocellular carcinoma patients after transcatheter arterial chemoembolization treatment with plasma cell-free DNA［J］. Eur J Gastroenterol Hepatol, 2019, 31: 885-892.
［5］ 郭 宇，陈规划. 肝细胞肝癌合并肝静脉、下腔静脉及右心房癌栓的诊断与治疗［J］. 中华肝脏外科手术学电子杂志，2013，2：53-55．
［6］ Chammas MC, Oliveira AC, D’avilla MJ, et al. Characterization of malignant portal vein thrombosis with contrast-enhanced ultrasonography［J］. Ultrasound Med Biol, 2019, 45: 50-55.
［7］ 李艳梅，李 鹏，赵卫威，等. 18氟-氟代脱氧葡萄糖PET/CT在癌栓鉴别诊断中的应用研究［J］. 中国临床医生杂志，2018，46：932-935．
［8］ 詹鹏超，李 臻，李 鑫，等. 血管腔内钳夹病理活检术2例分析［J］. 介入放射学杂志，2020，29：476-478．
［9］ Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial［J］. Lancet, 2018, 391: 1163-1173.
［10］ Kudo M. Immune checkpoint inhibition in hepatocellular carcinoma: basics and ongoing clinical trials［J］. Oncology, 2017, 92: 50-62.
［11］ Razi M, Jianping G, Xu H, et al. Conventional versus drug-eluting bead transarterial chemoembolization: a better option for treatment of unresectable hepatocellular carcinoma［J］. J Interv Med, 2021, 4: 11-14.
相似文献/References:
[1]张玥,王涛,岳振东,等.TIPS联合125I粒子植入治疗肝癌门脉主干癌栓及合并症的效果[J].介入放射学杂志,2020,29(01):89.
ZHANG Yue,WANG Tao,YUE Zhendong,et al.Clinical efficacy of TIPSS combined with 125I seeds implantation for HCC associated with main portal vein tumor thrombus and complications[J].journal interventional radiology,2020,29(01):89.